CIP2A and Miyoshi myopathy: Because of the poor tumorigenicity of MM.1R and MM.1S cells, U266 and 8226 cells were used to establish the MM murine model to test the efficacy of CIP2A.22 Two cell lines, CIP2A knockdown U266 (designed CIP2AKD-U266) and CIP2A overexpression 8226 (designed CIP2AOE-8226), were established respectively to further address the functional role of CIP2A in MM tumorigenesis in vivo.